Orchid Pharma today said it has received establishment inspection report (EIR) from the US health regulator for its Alathur facility in Tamil Nadu.
The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.
The facility was inspected by the USFDA on May 2017, it added.
Orchid Pharma stock shot up nearly 20 per cent to Rs 21.45 per scrip in the afternoon trade on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
